Skip To Main Content
Thierry Facon on Muck Rack

Thierry Facon

As seen in: Nature, Wiley Online Library, MDPI, The Lancet, HemOnc Today, Journal of Clinical Oncology, Texas Medical Center, Blood, Future Medicine, ONCOLOGY journal and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Thierry

Contact Thierry, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Toward a cure for multiple myeloma within a decade

|
By Mohamad Mohty Verified, Florent Malard, Thierry Facon, Jean-Luc Harousseau
| Nature Verified
Abstract Multiple myeloma (MM), long viewed as incurable, is entering a transformative era marked by deeper remissions, prolonged survival, and the realistic prospect of cure. The greatest opportunity lies at diagnosis, before genomic heterogeneity and immune escape limit therapeutic impact. High-risk smoldering MM provides a preclinical window where early intervention with targeted antibodies or combinations can delay progression and, as in some trials, improve survival.
Open in Who Shared Issue with article?

Daratumumab-lenalidomide and the immunosuppressive budget in myeloma - Authors' reply

|
By Salomon Manier, Margaret Macro, Xavier Leleu, Thierry Facon
| The Lancet Verified
We thank Yunfeng Fu and colleagues for their important comments on the IFM2017-03 trial 1 . We provide below the most accurate information available to address their remarks.
Open in Who Shared Issue with article?

"Daratumumab/Lenalidomide/Dexamethasone in Transplant-Ineligible Newly " by Thierry Facon, Philippe Moreau et al.

|
By Thierry Facon
| Texas Medical Center
Abstract In the MAIA study, daratumumab plus lenalidomide and dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). We report updated efficacy and safety from MAIA (median follow-up, 64.5 months), including a subgroup analysis by patient age (< 70, ≥70 to < 75, ≥75, and ≥80 years).
Open in Who Shared Issue with article?
See all 21 licensed articles (23 Total)